Cargando…
The efficacy and safety of antibodies targeting PD-1 for treatment in advanced esophageal cancer: A systematic review and meta-analysis
BACKGROUND: A novel therapy based on programmed death 1 (PD-1) inhibitors has been proved to be effective in advanced esophageal cancer. This article is a meta-analysis that aims to compare the efficacy and safety of anti-PD-1 therapy with chemotherapy in esophageal cancer. PATIENTS AND METHODS: Dat...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042180/ https://www.ncbi.nlm.nih.gov/pubmed/33784583 http://dx.doi.org/10.1016/j.tranon.2021.101083 |
_version_ | 1783678074548649984 |
---|---|
author | Lu, Yao Guan, Lulu Xu, Mengli Wang, Feng |
author_facet | Lu, Yao Guan, Lulu Xu, Mengli Wang, Feng |
author_sort | Lu, Yao |
collection | PubMed |
description | BACKGROUND: A novel therapy based on programmed death 1 (PD-1) inhibitors has been proved to be effective in advanced esophageal cancer. This article is a meta-analysis that aims to compare the efficacy and safety of anti-PD-1 therapy with chemotherapy in esophageal cancer. PATIENTS AND METHODS: Data were collected from eligible studies searched from PubMed, Web of Science, Cochrane Library, and Embase. Pooled hazard ratio (HR) for overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) was estimated to assess the efficacy of PD-1 inhibitors versus chemotherapy. The subgroup analysis was also performed to evaluate the OS benefits. The OR for the occurrence of treatment-related adverse effects was calculated to assess the safety of anti-PD-1 therapy. RESULTS: A total of 4 studies were analyzed. Compared with patients with chemotherapy, patients with anti-PD-1 therapy had a significant improvement in OS (HR = 0.79, 95% CI: 0.71–0.88, and P<0.001), but no significant relationship was observed in PFS (HR = 0.96, 95% CI: 0.76–1.20, and P = 0.69) and ORR (OR = 1.92, 95% CI: 0.98–3.72, and P = 0.06). A similar result was observed in esophageal squamous cell carcinoma. The significant predictor for treatment benefit alone was histology (P = 0.009). The incidence of grade 3 - 5 treatment-related adverse effects in anti-PD-1 therapy was distinctly lower than that in chemotherapy, but there is no statistical difference in all treatment-related adverse effects. CONCLUSION: Anti-PD-1 therapy significantly prolonged the OS, simultaneously lowered grade 3 - 5 treatment-related adverse effects versus chemotherapy. |
format | Online Article Text |
id | pubmed-8042180 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Neoplasia Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-80421802021-04-15 The efficacy and safety of antibodies targeting PD-1 for treatment in advanced esophageal cancer: A systematic review and meta-analysis Lu, Yao Guan, Lulu Xu, Mengli Wang, Feng Transl Oncol Original Research BACKGROUND: A novel therapy based on programmed death 1 (PD-1) inhibitors has been proved to be effective in advanced esophageal cancer. This article is a meta-analysis that aims to compare the efficacy and safety of anti-PD-1 therapy with chemotherapy in esophageal cancer. PATIENTS AND METHODS: Data were collected from eligible studies searched from PubMed, Web of Science, Cochrane Library, and Embase. Pooled hazard ratio (HR) for overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) was estimated to assess the efficacy of PD-1 inhibitors versus chemotherapy. The subgroup analysis was also performed to evaluate the OS benefits. The OR for the occurrence of treatment-related adverse effects was calculated to assess the safety of anti-PD-1 therapy. RESULTS: A total of 4 studies were analyzed. Compared with patients with chemotherapy, patients with anti-PD-1 therapy had a significant improvement in OS (HR = 0.79, 95% CI: 0.71–0.88, and P<0.001), but no significant relationship was observed in PFS (HR = 0.96, 95% CI: 0.76–1.20, and P = 0.69) and ORR (OR = 1.92, 95% CI: 0.98–3.72, and P = 0.06). A similar result was observed in esophageal squamous cell carcinoma. The significant predictor for treatment benefit alone was histology (P = 0.009). The incidence of grade 3 - 5 treatment-related adverse effects in anti-PD-1 therapy was distinctly lower than that in chemotherapy, but there is no statistical difference in all treatment-related adverse effects. CONCLUSION: Anti-PD-1 therapy significantly prolonged the OS, simultaneously lowered grade 3 - 5 treatment-related adverse effects versus chemotherapy. Neoplasia Press 2021-03-27 /pmc/articles/PMC8042180/ /pubmed/33784583 http://dx.doi.org/10.1016/j.tranon.2021.101083 Text en © 2021 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Lu, Yao Guan, Lulu Xu, Mengli Wang, Feng The efficacy and safety of antibodies targeting PD-1 for treatment in advanced esophageal cancer: A systematic review and meta-analysis |
title | The efficacy and safety of antibodies targeting PD-1 for treatment in advanced esophageal cancer: A systematic review and meta-analysis |
title_full | The efficacy and safety of antibodies targeting PD-1 for treatment in advanced esophageal cancer: A systematic review and meta-analysis |
title_fullStr | The efficacy and safety of antibodies targeting PD-1 for treatment in advanced esophageal cancer: A systematic review and meta-analysis |
title_full_unstemmed | The efficacy and safety of antibodies targeting PD-1 for treatment in advanced esophageal cancer: A systematic review and meta-analysis |
title_short | The efficacy and safety of antibodies targeting PD-1 for treatment in advanced esophageal cancer: A systematic review and meta-analysis |
title_sort | efficacy and safety of antibodies targeting pd-1 for treatment in advanced esophageal cancer: a systematic review and meta-analysis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042180/ https://www.ncbi.nlm.nih.gov/pubmed/33784583 http://dx.doi.org/10.1016/j.tranon.2021.101083 |
work_keys_str_mv | AT luyao theefficacyandsafetyofantibodiestargetingpd1fortreatmentinadvancedesophagealcancerasystematicreviewandmetaanalysis AT guanlulu theefficacyandsafetyofantibodiestargetingpd1fortreatmentinadvancedesophagealcancerasystematicreviewandmetaanalysis AT xumengli theefficacyandsafetyofantibodiestargetingpd1fortreatmentinadvancedesophagealcancerasystematicreviewandmetaanalysis AT wangfeng theefficacyandsafetyofantibodiestargetingpd1fortreatmentinadvancedesophagealcancerasystematicreviewandmetaanalysis AT luyao efficacyandsafetyofantibodiestargetingpd1fortreatmentinadvancedesophagealcancerasystematicreviewandmetaanalysis AT guanlulu efficacyandsafetyofantibodiestargetingpd1fortreatmentinadvancedesophagealcancerasystematicreviewandmetaanalysis AT xumengli efficacyandsafetyofantibodiestargetingpd1fortreatmentinadvancedesophagealcancerasystematicreviewandmetaanalysis AT wangfeng efficacyandsafetyofantibodiestargetingpd1fortreatmentinadvancedesophagealcancerasystematicreviewandmetaanalysis |